From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage
Variables
Group A
Group B
Group C
F
P- value
LogMAR BCVA
Baseline
2.006 ± 0.427
1.988 ± 0.463
2.05 ± 0.412
0.087
0.917
Month 3
0.706 ± 0.277
0.488 ± 0.189
0.463 ± 0.159
6.272
0.004